Accelerated hypofractionated radiotherapy with 3 Gy per fraction for central/ultra-central lung tumors: toxicity to mediastinal organs

被引:0
作者
Ito, Kei [1 ,3 ]
Minakami, Shota [1 ]
Nakajima, Yujiro [1 ,2 ]
Karasawa, Katsuyuki [1 ]
机构
[1] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Radiol, Div Radiat Oncol, Tokyo, Japan
[2] Komazawa Univ, Dept Radiol Sci, Tokyo, Japan
[3] Tokyo MetropolitanCancer & Infect Dis Ctr Komagome, Dept Radiol, Div Radiat Oncol, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo 1138677, Japan
关键词
Accelerated hypofractionated radiotherapy; lung neoplasms; mediastinal organs; ultra-central lung tumor; BODY RADIATION-THERAPY; CANCER; CARCINOMA; OUTCOMES; SURGERY;
D O I
10.1093/jjco/hyac181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Accelerated hypofractionated radiotherapy with 3 Gy per fraction is routinely performed for central lung tumors in Japan. However, the tolerable doses to mediastinal organs at risk during this procedure are unclear. This study aimed to clarify the rate of toxicities and tolerable doses to mediastinal organs. Methods Patients treated with accelerated hypofractionated radiotherapy using a total dose of 60-75 Gy, with 3 Gy per fraction, for central lung tumors (July 2009-April 2021) were retrospectively reviewed. We extracted patients who received >= 30 Gy irradiation to each mediastinal organ and analyzed dosimetric factors, including doses to 0.03, 0.5, 1, 4 and 10 mL of each organ, in relation to grade 3-5 toxicities, except for radiation pneumonitis. Results In total, 251 organs in 91 (ultra-central, 24) lesions were analyzed, with a median follow-up duration of 26 months (range, 4-94). The prescribed doses were 75/72/69/66/63/60 Gy for 52/14/16/3/2/4 lesions, respectively. Grade 3 bronchopulmonary hemorrhage was confirmed in two (2.2%) patients, whose tumors were located ultra-centrally. The two patients with toxicity received up to 74.5 and 71.6 Gy to the bronchus. Among patients who received 70 Gy or more to the bronchus, the incidence rate was 7% (2/28 patients). Conclusion The rate of severe toxicities was low (2.2%). Although we did not identify the dose tolerance of the organs, because of the low incidence rate, we did note that doses of >70 Gy to the bronchus were likely to cause bronchopulmonary hemorrhage. We evaluated the toxicity of accelerated hypofractionated radiotherapy for central lung tumors. The rate of severe toxicities was low (2.2%). The recommended threshold is 70 Gy to avoid bronchopulmonary hemorrhage.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 25 条
  • [1] Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
    Bezjak, Andrea
    Paulus, Rebecca
    Gaspar, Laurie E.
    Timmerman, Robert D.
    Straube, William L.
    Ryan, William F.
    Garces, Yolanda I.
    Pu, Anthony T.
    Singh, Anurag K.
    Videtic, Gregory M.
    McGarry, Ronald C.
    Iyengar, Puneeth
    Pantarotto, Jason R.
    Urbanic, James J.
    Sun, Alexander Y.
    Daly, Megan E.
    Grills, Inga S.
    Sperduto, Paul
    Normolle, Daniel P.
    Bradley, Jeffrey D.
    Choy, Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1316 - +
  • [2] Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors
    Chaudhuri, Aadel A.
    Tang, Chad
    Binkley, Michael S.
    Jin, Michelle
    Wynne, Jacob F.
    von Eyben, Rie
    Hara, Wendy Y.
    Trakul, Nicholas
    Loo, Billy W., Jr.
    Diehn, Maximilian
    [J]. LUNG CANCER, 2015, 89 (01) : 50 - 56
  • [3] Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review
    Chen, Hanbo
    Laba, Joanna M.
    Zayed, Sondos
    Boldt, R. Gabriel
    Palma, David A.
    Louie, Alexander V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (08) : 1332 - 1342
  • [4] STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CARCINOMA: FOUR-YEAR RESULTS OF A PROSPECTIVE PHASE II STUDY
    Fakiris, Achilles J.
    McGarry, Ronald C.
    Yiannoutsos, Constantin T.
    Papiez, Lech
    Williams, Mark
    Henderson, Mark A.
    Timmerman, Robert
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : 677 - 682
  • [5] Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
    Gomez, Daniel R.
    Blumenschein, George R., Jr.
    Lee, J. Jack
    Hernandez, Mike
    Ye, Rong
    Camidge, D. Ross
    Doebele, Robert C.
    Skoulidis, Ferdinandos
    Gaspar, Laurie E.
    Gibbons, Don L.
    Karam, Jose A.
    Kavanagh, Brian D.
    Tang, Chad
    Komaki, Ritsuko
    Louie, Alexander V.
    Palma, David A.
    Tsao, Anne S.
    Sepesi, Boris
    William, William N.
    Zhang, Jianjun
    Shi, Qiuling
    Wang, Xin Shelley
    Swisher, Stephen G.
    Heymach, John V.
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1672 - 1682
  • [6] Investigation of the freely available easy-to-use software 'EZR' for medical statistics
    Kanda, Y.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (03) : 452 - 458
  • [7] Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up
    Karasawa, Katsuyuki
    Hayakawa, Sara
    Machitori, Yumiko
    Shibata, Yukiko
    Ogawa, Hiroaki
    Ito, Kei
    Shimizuguchi, Takuya
    Kawamoto, Terufumi
    Nihei, Keiji
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2018, 17
  • [8] Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1)
    Kimura, Tomoki
    Nagata, Yasushi
    Harada, Hideyuki
    Hayashi, Shinya
    Matsuo, Yukinori
    Takanaka, Tsuyoshi
    Kokubo, Masaki
    Takayama, Kenji
    Onishi, Hiroshi
    Hirakawa, Koichi
    Shioyama, Yoshiyuki
    Ehara, Takeshi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 849 - 856
  • [9] A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer
    Li, Can
    Wang, Li
    Wu, Qian
    Zhao, Jiani
    Yi, Fengming
    Xu, Jianjun
    Wei, Yiping
    Zhang, Wenxiong
    [J]. MEDICINE, 2020, 99 (34) : E21715
  • [10] Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC)
    Lucas, John T. Jt
    Kuremsky, Jeffrey G.
    Soike, Mike
    Hinson, William W.
    Kearns, William T.
    Hampton, Carnell J.
    Blackstock, A. William
    Urbanic, James
    [J]. LUNG CANCER, 2014, 85 (01) : 59 - 65